NIH R01 · 2025
Engineered probiotic for the treatment of autoimmune diseases
PROJECT SUMMARY Approximately 50 million people suffer from one or more autoimmune diseases in the US alone. Over the last decades, the discovery of biologics has considerably improved the care for patients with autoimmune diseases. However, current treatments require weekly or more frequent injections and this can lead to missed doses and to poor patient compliance, especially in the younger population, resulting is inconsistent or sub- therapeutic drug levels. Since many of the therapeutics on the market or being developed to treat rheumatoid arthritis (RA), multiple sclerosis, and other T lymphocyte-mediated chronic autoimmune diseases are biologics, we propose a novel bioengineering…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.